o If you are taking zaleplon (Sonata) or zolpidem (Intermezzo), you should take the
medicine in bed and remain in bed for at least 4 hours.
• Do not take eszopiclone, zaleplon, and zolpidem with any other sleep medicines,
including over-the-counter medicines you can buy without a prescription. Do not drink
alcohol before taking these medicines because the combined effects can increase the
chances of side effects and adverse events.
• Read the patient Medication Guide every time you receive a prescription. The
Medication Guide will be updated with this new or other important information about
your medicine. It explains the important things that you need to know about the
medicine. These include the side effects, what the medicine is used for, how to take and
store it properly, and other things to watch out for when you are taking the medicine.
• For information on healthy sleep habits, visit the National Heart, Lung, and Blood
Institute for resources, including: Your Guide to Healthy Sleep and Insomnia: Relaxation
techniques and sleeping habits.
• We communicated safety information associated with insomnia medicines in January
2013 (risk of next-morning impairment with zolpidem), May 2013 (approved lower
recommended doses for zolpidem), and May 2014 (risk of next-morning impairment with
eszopiclone; lowered recommended dose).
• To help FDA track safety issues with medicines, report side effects from eszopiclone,
zaleplon, zolpidem, or other medicines to the FDA MedWatch program, using the
information in the “Contact FDA” box at the bottom of this page.
Additional Information for Health Care Professionals
• Complex sleep behaviors, in which patients engage in activities while they are not fully
awake, resulting in serious injuries and death have been reported with eszopiclone,
zaleplon, and zolpidem.
• These events can occur with just one dose of these medicines as well as after a longer
duration of treatment.
• Eszopiclone, zaleplon, and zolpidem are contraindicated in patients who report an
episode of complex sleep behavior after taking these insomnia medicines.
• Tell patients to discontinue their insomnia medicine if they experience an episode of
complex sleep behavior even if it did not result in a serious injury.
• When starting patients on eszopiclone, zaleplon, or zolpidem, follow the dosing
recommendations in the prescribing information and start with the lowest possible dose.
• Encourage patients to read the Medication Guide every time they fill their eszopiclone,
zaleplon, or zolpidem prescriptions, and remind them not to combine them with other
insomnia medicines, alcohol, or CNS depressants.
• We communicated safety information associated with insomnia medicines in January
2013 (risk of next-morning impairment with zolpidem), May 2013 (approved lower
recommended doses for zolpidem), and May 2014 (risk of next-morning impairment with
eszopiclone; lowered recommended dose).
• To help FDA track safety issues with medicines, report adverse events involving
eszopiclone, zaleplon, zolpidem, or other medicines to the FDA MedWatch program,
using the information in the “Contact FDA” box at the bottom of this page.